between OCD patients and controls (RT: 537739 vs 528750 ms; HR: 98.671 vs 98.272%), respectively. Neural generators of the N1 were estimated with the LORETA method, indicating a major source in the left temporoparietal region (Brodmann areas (BA) 19/37/39, Figure 1b ) and a weaker mirror image source on the right. Comparing individual source solutions statistically (voxel-wise), group H and the control group differed in the medial frontal (BA 23/24) and lateral temporo-occipital (BA 19) cortex (Figure 1c) . This is the first demonstration that BDV activity (amount of BDV-CICs) is associated with diseaserelevant and attention-related cognitive changes (increased N1) in humans, in particular in secondary visual areas and the anterior cingulate gyrus. The increased N1 amplitude in group H patients may be explained by defective thalamic filter mechanisms, given a proposed modulation by thalamic input to the cortex. 10 Indeed, functional neuroimaging studies 9 strongly suggest that OCD involves hyperactivity of striato-thalamo-cortical networks. The present findings are consistent with such a hyperactivity and suggest that this may be modulated by BDV infection possibly through interference of viral components with neurotransmitters (eg, glutamate and aspartate). 4 Future studies should validate these findings and further investigate possible mechanisms of this neurotropic virus in relation to altered cortical activity in psychiatric disorders.
SIR-Dopamine receptor genes have attracted considerable interest on account of their involvement in cortical processing, their evolutionary dynamics, and in view of growing prospects for the visualization of dopamine-related changes in brain activity. Variants of the dopamine D4 receptor gene (DRD4), in particular, have been studied extensively, following reports of their suspected role in Novelty Seeking, and related personality dimensions. 1 However, the issue remains unresolved owing to several potential confounders. While early investigations examined a 48 bp VNTR in exon III, conflicting findings with regard to personality traits have raised concerns that the grouping of alleles at this site may overstate what are only minor functional differences. 2 Others have pointed out a number of exon III alleles of unknown function nested in length variants. 3 More recently, the focus of attention has thus shifted towards DRD4 markers located in the gene's promoter region, on account of their relevance to gene expression. 4, 5 In particular, two variants are currently being regarded as modulators of DRD4 expression; namely, a 120 bp promoter length polymorphism (refSNP-ID rs4646984), and a À521T4C marker (refSNP-ID rs1800955) mapped to the gene's core promoter, 6 which was also implicated in the modulation of Extraversion in African Americans. 7 The present investigation was designed to test these polymorphisms as possible genetic determinants of personality traits in a larger population of healthy subjects.
A total of 104 Caucasian volunteers (52 males, mean age ¼ 29.177.5 years, and 52 females, mean age ¼ 28.177.6 years) were recruited from Regensburg University, or the Regensburg area, and completed the German version of the NEO-FFI questionnaire. The DRD4 promoter markers were assessed using PCR-based protocols previously described, 4, 5 and were confirmed to be in Hardy-Weinberg equilibrium. Allele and genotype frequencies were in close agreement with results from previous studies in Caucasians (f S ¼ 0.21 for allele grouping, see below; f T ¼ 0.54). For the promoter repeat, the lesser allele (S) was considered dominant to maximize balance in genotype ratios. For the À521T4C marker, we considered T the dominant allele to match the previous study. 7 One-way analyses of variance (ANOVA) identified carriers of the promoter 120 bp single repeat allele (short, S, as opposed to long, L, for 2 repeats) as exhibiting higher mean NEO-FFI Extraversion scores relative to other subjects (F ¼ 6.38; P ¼ 0.01, Table 1 ). Findings also matched the earlier study 7 in that carriers of the À521T allele scored lower on the Extraversion scale than did subjects homozygous for the C allele, although this difference did not prove significant in either gender. By contrast, positive evidence of gender effects emerged from an interaction model, including both promoter genotypes and gender, that corrected for age as a covariate of Extraversion (ANCOVA, F ¼ 2.46; df ¼ 8; P model ¼ 0.02). Together, these parameters accounted for over 17% of the variance in Extraversion, while the interaction did not affect any of the remaining personality scales at the 0.05 level of significance.
The possible phenotypic implications of a dysfunctional DRD4 promoter may be appraised from the study of animals that fail to express the DRD4. Applying this analogy, changes in cortical excitability or in behavioural sensitization are to be expected. 8 Alterations in cortical arousal, in turn, correspond to the cluster of approach traits, that is, Extraversion, Novelty Seeking and Sensation Seeking, in most models of biological substrates of personality. 9 It follows that genetic traits which reduce Extraversion, and demonstrably affect DRD4 gene expression in cellbased assays, 4 are highly likely to shape individual variability in approach behaviours. An additional interest in the gene's promoter region has arisen from a large body of 46 association studies addressing the personality of healthy subjects. 10 The authors stressed the general robustness of findings for the À521T4C variant, but did not include the more recent investigations of the 120 bp repeat. Our data suggest that both DRD4 promoter variants are involved in models of approach regardless of ethnic background, and would deserve closer scrutiny with regard to the role of gender. Little is known at present about the occurrence of variation nested in the duplicated 120 bp region. It is conceivable, however, that occasional interspersed single base exchanges will have less functional impact when compared to single-nucleotide variants in the three-fold shorter coding exon III VNTR, where they may introduce frameshifts or cause premature termination of transcription.
In an effort to clarify some of these issues, several groups have now begun resequencing the gene. 2 We are confident that this strategy will further contribute to better understanding of dopaminergic neurotransmission in Extraversion, often dubbed the 'engine' of human behaviour. 1 The same study also described evidence linking the putative protective genotype (ie 'A/A' for SNP rs1044925) to brain amyloid load and CSF cholesterol levels. ACAT1 is a strong AD candidate gene on both biochemical and positional grounds. First, cholesterol has been implicated in the regulation of b-amyloid peptide (Ab) production, and ACAT1, which regulates the cellular levels of free cholesterol and cholesteryl esters, has been shown to reduce the Ab levels in vitro.
2 Second, the gene encoding ACAT1 (SOAT1) is located near a chromosomal region (1q25) that full genome screens suggest may harbor a novel AD gene. 3, 4 We present here the results of a comprehensive genetic assessment of SOAT1 (including all three variants previously analyzed) 1 in the NIMH AD Genetics Initiative Study sample. 4, 5 Marginally significant findings were also assessed in a smaller, independent sample of sibships discordant for AD, the 'Consortium on AD Genetics' (CAG) Study sample. 6 In contrast to the previous findings, 1 we were unable to detect any consistent evidence of genetic association with the SNPs analyzed here.
AD is a genetically complex and heterogenous disorder. To date, mutations in three genes (APP, PSEN1, PSEN2) have been established to cause early-onset autosomal dominant forms of the disease. The fourth established AD gene, encoding the brain's main cholesterol transporter apolipoprotein E (APOE) on chromosome 19q13, acts as an AD susceptibility gene. 7 While the functional basis of this risk effect has not yet been fully elucidated, it seems that APOE-e4 is involved in the accumulation and aggregation of Ab, possibly via its role in brain cholesterol metabolism. 8 Several lines of evidence suggest that numerous risk-modifying genes exist in addition to APOE. However, despite their good candidacy, none of the putatively associated cholesterol-related genes (other than APOE) has yet received more than sporadic confirmation in independent studies. This situation is quite common in AD and may be attributed to a variety of factors including small gene effects, locus and allelic heterogeneity, population admixture (in case-control studies), as well as type-I error, and publication bias. 9, 10 In an attempt to corroborate Wollmer et al's 1 findings of a protective role of SOAT1 in AD, we comprehensively examined this gene in two independent family-based AD samples (NIMH and CAG), following a multistaged approach using both haplotype and single-locus analyses. Power calculations in 'PBAT' (v1. 2) 11 based on parameters reported by Wollmer and co-workers (ie recessive mode of inheritance, disease allele frequency of B0.6, odds ratio ¼ 0.6) revealed that at a ¼ 0.05 we have approximately 80% power in the NIMH families (and nearly 90% in NIMH and CAG combined) to detect a disease locus of the previously estimated effect size. In Stage I, we tested a total of eight database SNPs (including all SNPs originally tested) 1 for their amenability to FP-SBE genotyping (for technical details see Saunders et al 12 ), and as a preliminary assessment of linkage disequilibrium (LD) across the SOAT1 gene in 86 individuals of the NIMH sample (Table 1) . This yielded a total of four SNPs informative for followup in Stage II, which were assessed in a 'screening' subset of the NIMH sample consisting of 202 sibships discordant for AD (n ¼ 789: 440 affected, 348 unaffected; for a detailed description of the screening sample and power estimations, see Bertram et al
13
). All four SNPs genotyped here were predicted to reside within the same haplotype block (using Haploview), 14 and visual inspection of common haplotypes (ie frequency Z0.05) revealed that these could be tagged by three variants (ie rs1543876, rs2152320, rs1044925). While association analyses using 'FBAT' (v.1.5.3; Rabinowitz and Laird 15 and Horvath et al 16 ) as previously described 13 did not show any association with the originally associated variant rs1044925, we detected nominal evidence of association with another SNP that was not previously studied (ie rs2152320; P-value ¼ 0.04 in families with 'early/ mixed' onset age using 65 years as cutoff, data not
